文献速递肝病

奥贝胆酸单药治疗原发性胆汁性胆管炎患者的随机试验

A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis.
PubMed 文献 · Hepatology · 2018-01-29

这项国际随机双盲安慰剂对照2期研究评估奥贝胆酸(OCA)单药治疗原发性胆汁性胆管炎,患者随机接受安慰剂(n=23)、OCA 10 mg(n=20)或OCA 50 mg(n=16)每日一次治疗3个月。OCA组碱性磷酸酶较安慰剂显著降低(P<0.0001),瘙痒是最常见不良事件且呈剂量依赖性,开放标签扩展治疗6年期间生化改善持续。

要点

  • OCA 10 mg组碱性磷酸酶中位降低53.9%,OCA 50 mg组降低37.2%,安慰剂组降低0.8%(P<0.0001)。
  • 瘙痒是最常见不良事件,OCA 10 mg组15%、OCA 50 mg组38%因瘙痒停药。
  • 开放标签扩展治疗6年期间生化改善持续。

核心结论

  • OCA单药治疗显著改善碱性磷酸酶及其他预测长期临床结局改善的生化标志物。
  • 瘙痒随OCA治疗呈剂量依赖性增加。
  • 开放标签扩展治疗6年期间观察到生化改善。

研究设计与样本

  • 国际、随机、双盲、安慰剂对照2期研究。
  • 患者随机接受安慰剂(n=23)、OCA 10 mg(n=20)或OCA 50 mg(n=16)单药每日一次治疗3个月(1例随机化患者给药前退出)。
  • 疗效和安全性通过正在进行的6年开放标签扩展(N=28)持续监测。

主要发现

  • 研究结束时碱性磷酸酶较基线变化中位数(Q1,Q3):OCA 10 mg组-53.9%(-62.5,-29.3),OCA 50 mg组-37.2%(-54.8,-24.6),安慰剂组-0.8%(-6.4,8.7),P<0.0001。
  • 开放标签扩展治疗6年期间观察到相似的碱性磷酸酶降低。
  • OCA改善许多次要和探索性终点,包括γ-谷氨酰转肽酶、丙氨酸氨基转移酶、结合胆红素和免疫球蛋白M。
  • 瘙痒是最常见不良事件;因瘙痒停药者OCA 10 mg组为15%,OCA 50 mg组为38%。

关键数值与推荐

  • 主要终点为碱性磷酸酶从基线至双盲阶段结束的百分比变化。
  • 次要和探索性终点包括胆汁淤积、肝细胞损伤和法尼醇X受体激活标志物从基线至第3个月/提前终止的变化。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Obeticholic acid (OCA), a potent farnesoid X receptor agonist, was studied as monotherapy in an international, randomized, double-blind, placebo-controlled phase 2 study in patients with primary biliary cholangitis who were then followed for up to 6 years. The goals of the study were to assess the benefit of OCA in the absence of ursodeoxycholic acid, which is relevant for patients who are intolerant of ursodeoxycholic acid and at higher risk of disease progression. Patients were randomized and dosed with placebo (n = 23), OCA 10 mg (n = 20), or OCA 50 mg (n = 16) given as monotherapy once daily for 3 months (1 randomized patient withdrew prior to dosing). The primary endpoint was the percent change in alkaline phosphatase from baseline to the end of the double-blind phase of the study. Secondary and exploratory endpoints included change from baseline to month 3/early termination in markers of cholestasis, hepatocellular injury, and farnesoid X receptor activation. Efficacy and safety continue to be monitored through an ongoing 6-year open-label extension (N = 28). Alkaline phosphatase was reduced in both OCA groups (median% [Q1, Q3], OCA 10 mg -53.9% [-62.5, -29.3], OCA 50 mg -37.2% [-54.8, -24.6]) compared to placebo (-0.8% [-6.4, 8.7]; P < 0.0001) at the end of the study, with similar reductions observed through 6 years of open-label extension treatment. OCA improved many secondary and exploratory endpoints (including γ-glutamyl transpeptidase, alanine aminotransferase, conjugated bilirubin, and immunoglobulin M). Pruritus was the most common adverse event; 15% (OCA 10 mg) and 38% (OCA 50 mg) discontinued due to pruritus. CONCLUSION: OCA monotherapy significantly improved alkaline phosphatase and other biochemical markers predictive of improved long-term clinical outcomes. Pruritus increased dose-dependently with OCA treatment. Biochemical improvements were observed through 6 years of open-label extension treatment. (Hepatology 2018;67:1890-1902).

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Kowdley KV, Luketic V, Chapman R, et al. A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis. Hepatology. 2018. PMID: 29023915. doi:10.1002/hep.29569

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。